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Objective GPR119 is reportedly involved in regulating glucose metabolism and food intake in 39 
rodents, but little is known about its expression and functional significance in humans. To 40 
begin to assess the potential clinical importance of GPR119, was examined the distribution of 41 
GPR119 gene expression in humans. Materials/Methods Expression of GPR119 mRNA in 42 
fresh samples of normal human pancreas (n=19) and pancreatic islets (n=3) and in 43 
insulinomas (n=2) and glucagonomas (n=2), all collected at surgery, were compared with the 44 
mRNA expression of various receptors highly expressed and operative in human pancreatic 45 
islets. Results GPR119 mRNA was most abundant in the pancreas, followed by the 46 
duodenum, stomach, jejunum, ileum and colon. Pancreatic levels of GPR119 mRNA were 47 
similar to those of GPR40 mRNA and were higher than those of GLP1R and SUR1 mRNA, 48 
which are strongly expressed in human pancreatic islets. Moreover, levels of GPR119 mRNA 49 
in pancreatic islets were more than 10 times higher than in adjacent pancreatic tissue, as were 50 
levels of GPR40 mRNA. GPR119 mRNA was also abundant in two cases of insulinoma and 51 
two cases of glucagonoma, but was undetectable in a pancreatic acinar cell tumor. Similar 52 
results were obtained with mouse pancreatic islets, MIN6 insulinoma cells and alpha-TC 53 
glucagonoma cells. Conclusions The results provide evidence of an islet-gastrointestinal 54 




involvement in islet function. They also provide the basis for a better understanding of the 56 
potential clinical importance of GPR119.  57 
 58 
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Abbreviations  FFPE: formalin-fixed, paraffin-embedded. GLP1R: glucagon-like peptide 1 62 
receptor. GPR119: G protein-coupled receptor 119. GPR40: G protein-coupled receptor 40. 63 




1. Introduction 65 
Endogenous lipids such as free fatty acids and acylethanolamides are known to regulate 66 
glucose metabolism and food intake [1-3]. The underlying molecular mechanisms are not 67 
fully understood, however. Recently, four orphan G protein-coupled receptors (GPR40, 68 
GPR41, GPR43 and GPR120) were deorphaned and identified as fatty acid receptors [4-8]. 69 
Among those, we found that GPR40 is highly expressed in human pancreatic beta cells and is 70 
involved in regulating insulin secretion [9, 10]. In addition, GPR119 has been identified as a 71 
Gs-coupled receptor whose putative endogenous ligands include oleoylethanolamide (OEA) 72 
[11, 12] and possibly other lipids [13-16]. In vitro studies have implicated GPR119 in the 73 
regulation of insulin and incretin secretion [12, 14, 15, 17-20], and in vivo studies in rats and 74 
mice suggest its involvement in the regulation of glucose metabolism and feeding [11, 14, 18, 75 
19, 21-30]. That said, glucose metabolism in humans and mice may differ [31], and little is 76 
known about the expression and physiological significance of GPR119 in humans.  77 
In that context, we examined GPR119 gene expression in various human tissues, 78 
including fresh samples of pancreas and digestive tract collected at surgery. In addition, to 79 
gain further insight into the localization of GPR119 within the human pancreas, we compared 80 
GPR119 expression in human pancreatic islets and adjacent pancreatic tissue, as well as in 81 
insulinomas and glucagonomas, two very rare human tumors that possess the endocrine 82 




islet-gastrointestinal distribution of GPR119, its expression in pancreatic beta and alpha cells, 84 




2. Methods 86 
2.1. Subjects, tissue sampling and pancreatic islet isolation 87 
The clinical profiles of all patients enrolled in the present study are shown in Table 1. The 88 
study was performed in accordance with the Declaration of Helsinki and approved by the 89 
Ethical Committee on Human Research of Kyoto University Graduate School of Medicine. 90 
Signed informed consent was obtained from all patients.  91 
Normal human cerebral tissues (n=3) were collected from three patients at autopsy; one 92 
had died from amyotrophic lateral sclerosis, one from an iliopsoas muscle tumor and one 93 
from a ruptured aortic aneurysm. Normal tissues from the pancreas (n=19), esophagus (n=3), 94 
stomach (n=3), duodenum (n=3), jejunum (n=3), ileum (n=2), colon (n=3) and liver (n=2) 95 
were collected from 23 patients at tumor resection. In Fig. 1b and c, pancreatic tissues from 96 
four patients (patients 9, 10, 13 and 19 in Tables 1 and 2) were analyzed because of the 97 
limited amount of total RNA extracted from each patient. In all cases, sample margins 98 
contained no sign of tumor invasion, so the samples were considered to be tumor-free. In 99 
addition, samples of insulinoma (n=2), glucagonoma (n=1) and a pancreatic acinar cell tumor 100 
(n=1) were collected at surgery. From another patient with a glucagonoma, samples of normal 101 
pancreatic tissue and glucagonoma were obtained as formalin-fixed, paraffin-embedded 102 
(FFPE) sections. Islets were promptly isolated from pancreatic samples using the mince 103 




measured using high-performance liquid chromatography with a set of calibrators assigned 105 
by the Japan Diabetes Society (normal range 4.3-5.8%). A correlational analysis showed that, 106 
in Japan, estimated HbA1c values are 0.4% lower than those measured by the National 107 
Glycohemoglobin Standardization Program (NGSP) [32]. For that reason, we standardized 108 
the obtained HbA1c values to NGSP units by adding 0.4% to the measured values.  109 
 110 
2.2. Preparation and culture of mouse pancreatic islets, the MIN6 mouse insulinoma 111 
cell line and the alpha-TC mouse glucagonoma cell line  112 
Male 14-week-old C57BL/6 mice were purchased from Japan SLC (Shizuoka, Japan) and 113 
housed in a temperature-, humidity- and light-controlled room with free access to water and 114 
standard chow (Nosan Corporation, Kanagawa, Japan). Mouse pancreatic islets were isolated 115 
as previously described [33]. All experimental procedures were approved by the Animal 116 
Research Committee, Kyoto University Graduate School of Medicine, and were performed in 117 
accordance with institutional and national guidelines for animal experimentation. MIN6 cells 118 
were kindly provided by Dr. Junichi Miyazaki [34], and alpha-TC cells were obtained from 119 
American Type Culture Collection (ATCC) (Manassas, VA, USA). MIN6 cells were 120 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 15% FBS, while 121 
alpha-TC cells were maintained in RPMI 1640 medium supplemented with 10% FBS. Both 122 




Japan, Tokyo, Japan). The cells were incubated at 37°C under an atmosphere of humidified 124 
air (95%) and CO2 (5%). 125 
 126 
2.3. Total RNA preparation and cDNA synthesis 127 
Total RNAs were extracted from fresh tissues and cell lines using QIAGEN RNeasy Mini 128 
Kits [9, 10, 33], and from FFPE tissue sections using QIAGEN RNeasy FFPE Kits (QIAGEN 129 
K.K., Tokyo, Japan). The collected RNA was then treated with DNase I to remove any 130 
contaminating DNA. Additionally, total RNAs from human brain, thyroid, heart, lung, 131 
trachea, kidney, esophagus, liver, skeletal muscle, adipose tissue, spleen, bladder, prostate, 132 
placenta and cervix were obtained from Life Technologies Japan. Total RNAs from stomach, 133 
small intestine, colon, pancreas, testis, ovary and uterus were from Takara Clontech (Tokyo, 134 
Japan). Finally, total RNAs from hypothalamus were obtained from two sources, Life 135 
Technologies Japan and BioChain Institute (Hayward, CA, USA). First strand cDNA was 136 
synthesized by random hexamer-primed reverse transcription using SuperScript II reverse 137 
transcriptase (Life Technologies Japan).  138 
 139 
2.4. Quantification of human and mouse receptor gene expression 140 
Levels of GPR119 mRNA in the pancreas and pancreatic islets were compared with those of 141 




(ABCC8 or SUR1) mRNA, which are reportedly expressed in human pancreatic islets and 143 
involved in insulin secretion [9, 10]. Messenger RNA levels were quantified using the 144 
TaqMan PCR method with an ABI PRISM 7700 Sequence Detector (Life Technologies 145 
Japan), as described previously [9, 10]. To estimate the copy number of each mRNA, 146 
standard curves were generated using oligo DNA fragments (Sigma Genosys Japan, Tokyo, 147 
Japan) containing the PCR amplicon region. The receptor mRNA levels were normalized to 148 
the level of GAPDH mRNA and expressed as the receptor/GAPDH [copy/copy] ratio [9]. The 149 
sequences of the primers and probes (Life Technologies Japan) used for the quantification of 150 
the mRNAs were as follows: human GPR119 (NM_178471), 151 
CCATGGCTGGAGGTTATCGA (forward), GCTCCCAATGAGAACAGACACA (reverse) 152 
and 6-carboxyfluorescein 153 
(FAM)-CCCCACGGACTCCCAGCGACT-6-carboxytetramethylrhodamine (TAMRA) 154 
(probe); mouse GPR119 (NM_181751), TCCAGAGAGGACCAGAGAAAGC (forward), 155 
GCAGCGTCTTAGCCATCGA (reverse) and 156 
FAM-TCACATCGTCACTATCAGCCATCCGG-TAMRA (probe); mouse GPR40 157 
(NM_194057), GGCTTTCCATTGAACTTGTTAGC (forward), 158 
CCCAGATGGAGAGTGTAGACCAA (reverse) and 159 
FAM-TGTCCCACGCTAAACTGCGACTCACTC-TAMRA (probe); mouse GADPH 160 




and FAM-CAGAAGACTGTGGATGGCCCCTC-TAMRA (probe). The sequences of the 162 
primers and probes used for quantification of the human GPR40, GLP1R, ABCC8 (SUR1) 163 
and GAPDH mRNAs are described elsewhere [9, 10].  164 
 165 
2.5. Data analysis on metabolic parameters   166 
We evaluated beta cell function and systemic insulin resistance using the insulinogenic index 167 
(n=10) [35] or the homeostasis model assessment of beta cell function (HOMA-beta) (n=14) 168 
and insulin resistance (HOMA-IR) (n=14) [36], respectively. The difference between the 169 
numbers of patients whose test data were included in the HOMA indices and insulinogenic 170 
index reflects the availability of data for plasma glucose and serum insulin levels at the 30 171 
min mark during the oral glucose tolerance test (OGTT). The area under the serum insulin 172 
concentration-time curve (insulin AUC) was calculated from the OGTT data using the 173 
trapezoidal rule. Patients 7, 12 and 17 were excluded from analysis of the correlation between 174 
pancreatic GPR119 mRNA levels and metabolic parameters, because of a diagnosis of 175 
insulinoma (patient 7) or percutaneous transhepatic biliary drainage (patients 12 and 17). 176 
None of the patients were treated with oral glucose-lowering agents or with insulin. Table 2 177 
shows the metabolic parameters of the patients whose pancreatic tissues were examined; the 178 





2.6. Statistical analysis   181 
Correlations between pancreatic GPR119 mRNA levels and clinical parameters were 182 
examined using the simple regression analysis. Differences between groups were assessed 183 
using unpaired two-tailed t-tests or ANOVA where applicable. Values of p < 0.05 were 184 




3. Results 186 
3.1 Expression of GPR119 mRNA in normal human tissues 187 
We initially tested for GPR119 mRNA in samples of commercially available total RNA from 188 
normal human tissues. We found that the transcript was most abundant in the pancreas, 189 
followed by the gastrointestinal tract (small intestine, colon and stomach) and the testis (Fig. 190 
1A). GPR119 mRNA was not detected in any other human tissue tested. To gain further 191 
insight into GPR119 gene expression humans and verify the aforementioned distribution 192 
profile, we also examined tissues obtained at surgery or autopsy. Among those samples, 193 
GPR119 mRNA was most abundant in the pancreas, followed by the duodenum, stomach, 194 
jejunum, ileum and colon, but was not detected in the esophagus, liver or cerebrum (Fig. 1B).  195 
 196 
3.2 Expression of GPR119, GPR40, GLP1R and SUR1 mRNAs in the human 197 
pancreas 198 
Using specimens from four patients, we compared the pancreatic expression of GPR119 199 
mRNA with that of GPR40, GLP1R and SUR1 mRNA in the same samples. We found that 200 
pancreatic levels of GPR119 mRNA were comparable to those of GPR40 mRNA and were 201 





3.3. Expression of GPR119 and GPR40 mRNA in isolated pancreatic islets and 204 
adjacent pancreatic tissue 205 
We next assessed GPR119 expression in pancreatic islets from three patients (Fig. 2A). 206 
Levels of GPR119 mRNA in freshly isolated islets were approximately 13 to 16 times higher 207 
than in the adjacent pancreatic tissue from the same patients. We also analyzed GPR40 208 
expression and found that levels of GPR119 and GPR40 mRNA were similar in isolated 209 
pancreatic islets (Fig. 2B).  210 
 211 
3.4. Expression of GPR119 and GPR40 mRNA in human insulinomas and 212 
glucagonomas 213 
We also assessed expression of GPR119 and GPR40 mRNA using total RNAs extracted from 214 
specimens of fresh insulinomas (n=2), a glucagonoma (n=1) and a pancreatic acinar cell 215 
tumor (n=1), as well as from FFPE glucagonoma tissue sections from another patient (n=1). 216 
In the two cases of insulinoma, tumoral GPR119 mRNA levels were comparable to those in 217 
pancreatic islets (Fig. 3A). A considerable amount of GPR119 mRNA was also detected in 218 
tissue extracts from the glucagonoma (Fig. 3A), where GPR40 mRNA was not detectable 219 
(Fig. 3C). Levels of GPR119 mRNA in tissue extracts from FFPE sections of non-tumor 220 
pancreas and glucagonoma were similar to those in the corresponding specimens collected at 221 




glucagonoma sections (Fig. 3D), which is consistent with the level in the fresh tumor 223 
specimen (Fig. 3, C and D). Neither GPR119 nor GPR40 mRNAs was detectable in the 224 
acinar cell tumor specimen (Fig. 3, A and C).  225 
 226 
3.5. Expression of GPR119 and GPR40 mRNAs in mouse pancreatic islets, MIN6 227 
insulinoma cells and alpha-TC glucagonoma cells 228 
To further explore GPR119 expression in pancreatic islet cells, we measured GPR119 mRNA 229 
levels in mouse pancreatic islets, MIN6 insulinoma cells and alpha-TC glucagonoma cells. 230 
We also assessed expression of GPR40 mRNA in the same samples, as GPR40 is known to 231 
be preferentially expressed in pancreatic beta cells in both rodents and humans [4, 9, 10, 37]. 232 
High levels of GPR119 mRNA, comparable to those of GPR40 mRNA, were detected in 233 
mouse pancreatic islets (Fig. 4, A and B). Likewise, similar levels of GPR119 and GPR40 234 
mRNA were detected in MIN6 cells (Fig. 4, A and B). On the other hand, the level of 235 
GPR119 mRNA in alpha-TC cells was approximately 1/7 that in MIN6 cells, and no GPR40 236 
mRNA was detected in alpha-TC cells (Fig. 4, A and B).  237 
 238 
3.6. Correlation between pancreatic GPR119 mRNA expression and the 239 
insulinogenic index and HOMA-beta in humans 240 




initially assessed GPR119 mRNA expression in non-tumor pancreatic tissue samples from 19 242 
patients with various pancreatic tumors (Table 1). High levels of GPR119 mRNA, 243 
comparable to those in the four cases summarized in Fig 1, A and B (0.336±0.037 vs. 244 
0.319±0.090), were detected in all of the tissue samples analyzed (Table 2).  Because the 245 
inter-individual variation in the pancreatic GPR119 mRNA level (n=19) was high, to begin to 246 
explore the physiological importance of GPR119 in humans, we evaluated the relationship 247 
between pancreatic GPR119 mRNA levels and various clinical parameters. We found that 248 
GPR119 mRNA expression did not significantly differ among the head, body and tail portions 249 
of the pancreas (Table 3), nor did it correlate significantly with age (Supplemental Table S1).  250 
When we then evaluated the correlation between pancreatic GPR119 gene expression 251 
and several metabolic parameters, including glucose and triglyceride metabolism (Table 2), 252 
we found that pancreatic GPR119 mRNA levels did not correlate significantly with BMI, 253 
fasting plasma glucose (FPG), 2-h post-OGTT plasma glucose (2h-PG), insulin AUC or 254 
fasting serum triglyceride levels (Supplemental Table S1), nor did they correlate significantly 255 
with HbA1c levels or HOMA-IR values (Supplemental Table S1, Fig. 5, A and B). By 256 
contrast, pancreatic GPR119 mRNA levels positively and significantly correlated with the 257 
insulinogenic index (n=10, p=0.004, r=0.817) (Fig. 5C) and with HOMA-beta values (n=14, 258 
p=0.043, r=0.547) (Fig. 5D). Using the same patient data used to calculate the insulinogenic 259 




mRNA expression and HbA1c levels and HOMA-IR values, which confirmed the absence of 261 





4. Discussion 264 
Our findings demonstrate for the first time that GPR119 is highly expressed in human 265 
pancreatic islets, where the level of GPR119 expression is enriched more than 10-fold, as 266 
compared to adjacent areas of the pancreas in the same individuals. We also found that 267 
pancreatic levels of GPR119 mRNA are similar to those of GPR40 mRNA and are higher 268 
than those of GLP1R and SUR1 mRNA. Likewise, the level of GPR119 mRNA in isolated 269 
pancreatic islets is similar to that of GPR40 mRNA and higher than those of SUR1 and 270 
GLP1R mRNA [9, 10]. This is noteworthy, as these receptors are reported to be abundantly 271 
expressed in human pancreatic islets.  272 
We observed that substantial amounts of GPR119 mRNA are expressed in human 273 
insulinomas (n=2) and glucagonomas (n=2), and that the tumoral levels of the transcript are 274 
comparable to those in pancreatic islets. A similar pattern of GPR119 mRNA expression was 275 
also detected with mouse pancreatic islets, MIN6 insulinoma cells and alpha-TC 276 
glucagonoma cells. Thus GPR119 appears to be highly expressed in both beta and alpha cells 277 
in human and mouse pancreatic islets. Moreover, our observation that the expression levels of 278 
GPR119 and GPR40 mRNAs in human pancreatic islets are similar and are higher than that 279 
of SUR1 mRNA is noteworthy because SUR1 is reported to be abundantly expressed in both 280 
beta and alpha cells and is involved in the regulation of islet function, including insulin and 281 




pancreatic islet function in humans. Consistent with that idea, pancreatic GPR119 mRNA 283 
levels correlated positively with two indices of beta cell function: the insulinogenic index and 284 
the HOMA-beta. Collectively, therefore, the present findings provide evidence for the 285 
possible involvement of GPR119 in islet function, perhaps affecting insulin secretion.  286 
Using fresh tissue samples collected at surgery, we observed that, in humans, GPR119 287 
mRNA is abundantly expressed in the small intestine, stomach and colon, but not in the 288 
esophagus. In rodents, GPR119 appears to be expressed in enteroendocrine cells, including L 289 
and K cells, and to be involved in the regulation of incretin and polypeptide YY secretion. In 290 
humans, enteroendocrine cells are distributed throughout the gastrointestinal tract, but not in 291 
the esophagus. Although details of GPR119 expression and its function in the human 292 
gastrointestinal tract will require further investigation, our findings are consistent with the 293 
idea that GPR119 is expressed in enteroendocrine cells and is involved in incretin and peptide 294 
YY secretion.  295 
We detected no GPR119 mRNA in the human hypothalamus, brain or cerebrum, which 296 
is consistent with a recent report that GPR119 mRNA is not significantly expressed in the 297 
human brain or hypothalamus [19]. Although earlier reports using OEA (a putative GPR119 298 
ligand) and a synthetic OEA analogue in rats suggest GPR119 may mediate signalling 299 
leading to reduced food intake and body weight, OEA appears to act mainly in peripheral 300 




highly expressed in the human stomach and duodenum is consistent with the notion that 302 
GPR119 is involved in regulating food intake in humans, as the bipolar vagal afferents 303 
involved in regulating feeding are known to project to the stomach and upper intestine [42, 304 
43].  305 
In summary, the present study demonstrates that, in humans, GPR119 mRNA is 306 
abundantly expressed in healthy pancreatic islets and the human gastrointestinal tract, and in 307 
insulinomas and glucagonomas. The results provide evidence of an islet-gastrointestinal 308 
distribution of GPR119, its expression in pancreatic beta and alpha cells, and its possible 309 
involvement in islet function. They also provide the basis for a better understanding of the 310 
potential clinical importance of GPR119.  311 
 312 
4.1. Limitations of the present study 313 
Our study has several limitations that should be noted. 314 
1. To our knowledge, no specific antibody against human GPR119 is available, so we 315 
were unable to assess expression of GPR119 protein.  316 
2. The enrolled subjects were tumor-bearing patients, though the tumors were at an early 317 
stage or benign, and were resectable. Pancreatic biopsy is rarely performed because of 318 
the risk of pancreatitis, and is not justified in those without severe illness [44]. 319 




pancreatic tissue is very vulnerable to postmortem autolysis, specimens obtained at 321 
surgery offer substantial advantages for precise analysis of GPR119 expression. 322 
Nonetheless, possible weight loss and the paracrine effects of pancreatic cancer cells on 323 
beta cells could have influenced the correlation study.  324 
3. Patients enrolled in the present study were not severely diabetic (HbA1c was less than 325 
7.2%), nor were they overweight or obese (BMIs were less than 25). Thus clarification 326 
of the pathophysiological role of GPR119 in human diabetes and obesity must await 327 
further investigation in patients with a wider range of glucose tolerances and BMIs.  328 
4. Plasma glucagon levels were not determined in the preoperative evaluation, and were 329 
not included in the present study. Beta cell mass is known to be much greater than alpha 330 
cell mass in pancreatic islets, and correlations between GPR119 mRNA levels and 331 
indices for beta cell function seem plausible, but may underestimate the involvement of 332 
GPR119 in the glucagon secretion. Further studies will be necessary to clarify the role 333 
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Figure Legends 356 
Fig. 1 - Expression of GPR119 mRNA in human tissues. All receptor mRNA levels were 357 
normalized to the level of GAPDH mRNA in the same tissue. A, GPR119 mRNA levels in 358 
commercially obtained samples of human total RNA from the indicated tissues. B, GPR119 359 
mRNA expression in the indicated human tissues collected at autopsy (cerebrum) or at 360 
surgery (all tissues except cerebrum). C, Expression of GPR119, GPR40, GLP1R and SUR1 361 
mRNA in normal human pancreatic tissue collected at surgery (n=4). The specimens used 362 
were the same as in panel B. Receptor mRNA levels in panels B and C are expressed as 363 
means ± SEM. Black bar, GPR119; white bar, GPR40; hatched bar, GLP1R; double-hatched 364 
bar, ABCC8 (SUR1).  365 
 366 
Fig. 2 - Expression of GPR119 mRNA in human pancreatic islets and adjacent pancreatic 367 
tissue. All receptor mRNA levels were normalized to the level of GAPDH mRNA in the same 368 
tissue. A, Comparison of GPR119 mRNA expression in pancreatic islets and adjacent 369 
pancreatic tissue from three patients. White bars, pancreas; black bars, pancreatic islets. B, 370 
Comparison of GPR119 and GPR40 mRNA expression in pancreatic islets and adjacent 371 
pancreatic tissue. The tissue samples used were the same as in panel A (n=3). Levels of 372 
GPR119 and GPR40 mRNA are expressed as means ± SEM. White bars, pancreas; black 373 





Fig. 3 - Expression of GPR119 and GPR40 mRNA in human pancreatic islets, insulinomas 376 
and glucagonomas. A and C, Expression of GPR119 (A) and GPR40 (C) mRNA in non-tumor 377 
pancreas (Pancreas), pancreatic islets (Islets), insulinomas (INS), a glucagonoma (GLU) and 378 
a pancreatic acinar cell tumor (ACI). B and D, Expression of GPR119 (B) and GPR40 (D) 379 
mRNA in extracts from non-tumor pancreatic and glucagonoma tissue sections (n=1 each). 380 
All receptor mRNA levels were normalized to the level of GAPDH mRNA in the same tissue. 381 
GPR119 and GPR40 mRNA levels in pancreas and pancreatic islets are expressed as means ± 382 
SEM. White bars, pancreas; black bars, pancreatic islets; hatched bars, insulinomas; 383 
double-hatched bars, glucagonomas.  384 
 385 
Fig. 4 - Expression of GPR119 and GPR40 mRNAs in mouse pancreatic islets, insulinoma 386 
and glucagonoma. Expression of GPR119 (A) and GPR40 (B) mRNAs pancreatic islets, 387 
MIN6 insulinoma cells and alpha-TC glucagonoma cells. All receptor mRNA levels were 388 
normalized to the level of GAPDH mRNA in the same tissue. Black bars, pancreatic islets; 389 
hatched bars, MIN6 cells; double hatched bars, alpha-TC cells.  390 
 391 
Fig. 5 - Correlations between human pancreatic GPR119 mRNA levels and parameters of 392 




insulinogenic index (n=10) (C) and HOMA-beta values (n=14) (D). All GPR119 mRNA 394 
levels were normalized to the level of GAPDH mRNA in the same tissue. Simple regression 395 
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Table 1. Clinical profiles of the patients who underwent pancreatectomy and tissues analyzed 
Patient Age(years) Sex(M/F) Disease Tissue analyzed 
1 26 M Pancreatic cancer Pancreas (tail) 
2 47 F Pancreatic cancer Pancreas (head) 
3 53 F Pancreatic cancer Pancreas (head) 
4 54 M Pancreatic cancer Pancreas (head) 
5 55 F Pancreatic cancer Pancreas (body) 
6 57 M Islet cell tumor (nonfunctional) Pancreas (tail) 
7 59 F Insulinoma Pancreas (head), insulinoma 
8 60 M Pancreatic cancer Pancreas (body) 
9 60 M Pancreatic cancer Pancreas (head) 
10 61 F Papilla cancer  Pancreas (head) 
11 63 F Islet cell tumor (nonfunctional) Pancreas (body) 
12 63 M Pancreatic cancer Pancreas (head) 
13 64 M Pancreatic cancer Pancreas (body) 
14 69 M Pancreatic cancer Pancreas (head) 
15 71 F Pancreatic cancer Pancreas (body) 
16 72 F Pancreatic cancer Pancreas (body) 
17 72 F Pancreatic cancer Pancreas (head) 
18 75 M Pancreatic cancer Pancreas (head) 
19 76 M Duodenal cancer Pancreas (head) 
20 27 F Insulinoma Insulinoma 
21 23 F Glucagonoma Glucagonoma 
22 41 F Acinar cell tumor Acinar cell tumor 
23 34  F Glucagonoma Glucagonoma 
Patients were premedicated with 0.01 mg/kg atropine sulfate i.m. and 0.2 mg/kg diazepam orally before surgery. Tissues were sampled under general 
anesthesia with 35% O2, 65% N2O and 0.5-1.5% sevoflurane. Neuromuscular blockade was provided by vecuronium bromide at an initial dose 0.1 
mg/kg and supplemented as required.  

























1 24.2  4.7  6.7  32  5.1 9.6  83.0  124.4  1.23  0.183 
2 19.7  7.2  12.6  53  7.1 36.6  100.1  102.1  2.26  0.334 
3 17.7  4.4  6.8  24  5.1 2.8  62.7  50.8  1.54  0.430 
4 22.3  4.9  9.1  18  5.7 3.7  17.8  40.3  0.89  0.112 
5 24.6  5.1  8.3  25  5.1 5.7  42.8  54.0  1.20  0.235 
6 25.7  6.1  ND ND 5.6 24.0  ND 112.60  1.48  0.342 
7* 22.1  2.0  4.9  84  4.7 2.5  ND -61.3  0.86  0.419 
8 18.0  5.3  10.8  12  6.3 3.3  23.6  25.1  1.76  0.063 
9 19.6  4.3  11.4  ND 5.4 2.0  ND 40.8  2.01  0.228 
10 20.0  4.6  6.9  24  5.0 8.4  163.7  130.7  1.40  0.583 
11 22.8  5.5  13.6  ND 6.7 8.5  ND 58.0  2.28  0.483 
12† 24.2  4.8  ND ND 6.5 ND ND ND 1.01  0.582 
13 23.3  5.2  10.7  18  5.8 8.5  11.1  70.8  1.29  0.185 
14 24.3  ND ND ND 7.1 ND ND ND 0.95  0.272 
15 23.5  4.9  8.9  ND 6.2 10.3  ND 113.8  1.99  0.492 
16 18.4  6.1  ND ND 6.5 ND ND ND 2.03  0.306 
17† 16.8  5.1  ND ND 5.8 ND ND ND 1.02  0.631 
18 22.6  5.4  8.3  51  6.2 6.8  47.8  48.3  1.60  0.219 
19 20.3  4.2  6.8  48  5.4 3.0  103.1  81.0  0.49  0.279 
The patient numbers correspond to those in Table 1. *Patient 7 was diagnosed as having an insulinoma. †Patients 12 and 17 were treated with 
percutaneous transhepatic biliary drainage (PTBD). Because of the unavailability of blood samples, some of the metabolic profiles were not determined 
(shown as ND). FPG, fasting plasma glucose level; 2h-PG, 2-h post-OGTT plasma glucose level; ND, not determined  







GPR119 mRNA levels are expressed as means ± SEM. Comparisons were made 
using unpaired two-tailed t-tests. *p values are vs the head.  
Pancreatic region(s) GPR119 mRNA level n   p* 
Head 0.372 ± 0.052 11 - 
Body 0.294 ± 0.069 6 0.388 
Tail 0.262 ± 0.079 2 0.367 
Body and tail 0.286 ± 0.053 8 0.264 
Supplemental Table S1: Correlation between pancreatic GPR119 mRNA levels 













The correlations between pancreatic GPR119 mRNA levels and various parameters 
were examined using simple regression analysis. FPG, fasting plasma glucose level; 
2h-PG, 2-h post-OGTT plasma glucose level.  
 
 
n  r p 
 Age 19 0.290 0.256 
 BMI 19 0.017 0.597 
 FPG 15  0.0001 0.967 
 2h-PG 13 0.005 0.825 
 Insulin-AUC 10 0.042 0.570 
 Triglyceride 19  0.0004 0.939 
 HbA1c 10 0.109 0.350 
 14    0.000048 0.981 
 HOMA-IR 10 0.039 0.583 
 14 0.047 0.454 
